Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Juvenile Macular Degeneration Pipeline Drugs Market Overview
Juvenile Macular Degeneration is mostly found in the form of Stargardt disease. Stargardt’s disease can occur with symptoms that include blurry or fuzzy vision, dark, empty spots in the center of vision, and difficulty reading or performing detail work.
The Juvenile Macular Degeneration pipeline drugs market research report provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects.
Key Targets in the Juvenile Macular Degeneration Pipeline Drugs Market
The key targets of the Juvenile Macular Degeneration pipeline drugs market are Retinal Specific ATP Binding Cassette Transporter, Acetylcholinesterase, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Complement C5, Complement Factor D, Peroxisome Proliferator Activated Receptor Alpha, Peroxisome Proliferator Activated Receptor Delta, Peroxisome Proliferator Activated Receptor Gamma, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Retinoid Isomerohydrolase, Retinol Binding Protein 4, and Transthyretin.
Juvenile Macular Degeneration Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Juvenile Macular Degeneration Pipeline Drugs Market
The mechanisms of action of the Juvenile Macular Degeneration pipeline drugs market are Retinal Specific ATP Binding Cassette Transporter Activator, Acetylcholinesterase Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Complement C5 Inhibitor, Complement Factor D Inhibitor, Peroxisome Proliferator Activated Receptor Alpha Agonist, Peroxisome Proliferator Activated Receptor Delta Agonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/KInhibitor, Retinoid Isomerohydrolase Inhibitor, Retinol Binding Protein 4 Inhibitor, and Transthyretin Inhibitor.
Juvenile Macular Degeneration Pipeline Drugs Market, by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Juvenile Macular Degeneration Pipeline Drugs Market
The routes of administration in the Juvenile Macular Degeneration pipeline drugs market are oral, intravitreal, intraocular, ophthalmic, and subcutaneous.
Juvenile Macular Degeneration Pipeline Drugs Market, by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Juvenile Macular Degeneration Pipeline Drugs Market
The molecule types in the Juvenile Macular Degeneration pipeline drugs market are gene therapy, small molecule, cell therapy, aptamer, antisense oligonucleotide, antisense RNAi oligonucleotide, and recombinant enzyme.
Juvenile Macular Degeneration Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Juvenile Macular Degeneration Pipeline Drugs Market Companies
Some of the key companies in the Juvenile Macular Degeneration pipeline drugs market are Astellas Pharma Inc, IVERIC bio Inc, 4P-Pharma SAS, Alkeus Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Alpine Biotherapeutics Corp, Applied Genetic Technologies Corp, Beam Therapeutics Inc, Belite Bio Inc, and Biophytis SA.
Juvenile Macular Degeneration Pipeline Drugs Market, by Key Companies
To know more about key companies, download a free report sample
Market Report Overview
| Key Targets | Retinal Specific ATP Binding Cassette Transporter, Acetylcholinesterase, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Complement C5, Complement Factor D, Peroxisome Proliferator Activated Receptor Alpha, Peroxisome Proliferator Activated Receptor Delta, Peroxisome Proliferator Activated Receptor Gamma, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Retinoid Isomerohydrolase, Retinol Binding Protein 4, and Transthyretin |
| Key Mechanisms of Action | Retinal Specific ATP Binding Cassette Transporter Activator, Acetylcholinesterase Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Complement C5 Inhibitor, Complement Factor D Inhibitor, Peroxisome Proliferator Activated Receptor Alpha Agonist, Peroxisome Proliferator Activated Receptor Delta Agonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/KInhibitor, Retinoid Isomerohydrolase Inhibitor, Retinol Binding Protein 4 Inhibitor, and Transthyretin Inhibitor |
| Key Routes of Administration | Oral, Intravitreal, Intraocular, Ophthalmic, and Subcutaneous |
| Key Molecule Types | Gene Therapy, Small Molecule, Cell Therapy, Aptamer, Antisense Oligonucleotide, Antisense RNAi Oligonucleotide, and Recombinant Enzyme |
| Key Companies | Astellas Pharma Inc, IVERIC bio Inc, 4P-Pharma SAS, Alkeus Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Alpine Biotherapeutics Corp, Applied Genetic Technologies Corp, Beam Therapeutics Inc, Belite Bio Inc, and Biophytis SA |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Ophthalmology).
- Reviews of pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Juvenile Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
- Evaluation of Juvenile Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
- Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Ophthalmology)
- Classify potential new clients or partners in the target demographic
- Develop tactical initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
- Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline
Alkeus Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Alpine Biotherapeutics Corp
Applied Genetic Technologies Corp
Astellas Pharma Inc
Beam Therapeutics Inc
Belite Bio Inc
Biophytis SA
Brooklyn ImmunoTherapeutics Inc
Cardax Inc
Coave Therapeutics
Copernicus Therapeutics Inc
Curative Biotechnology Inc
Fera Pharmaceuticals LLC
Generation Bio Co
Grupo Ferrer Internacional SA
IVERIC bio Inc
jCyte Inc
Katairo GmbH
Kubota Vision Inc
Lysoclear Inc
Mediphage Bioceuticals Inc
Nanoscope Therapeutics Inc
Oak bay Biosciences Ltd
ProQR Therapeutics NV
Ray Therapeutics Inc
ReVision Therapeutics Inc
Saliogen Therapeutics Inc
Shape Therapeutics Inc
Spark Therapeutics Inc
Splice Bio SL
Stargazer Pharmaceuticals Inc
Table of Contents
Frequently asked questions
-
What are the targets of the Juvenile Macular Degeneration pipeline drugs market?
The targets of the Juvenile Macular Degeneration pipeline drugs market are Retinal Specific ATP Binding Cassette Transporter, Acetylcholinesterase, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Complement C5, Complement Factor D, Peroxisome Proliferator Activated Receptor Alpha, Peroxisome Proliferator Activated Receptor Delta, Peroxisome Proliferator Activated Receptor Gamma, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K, Retinoid Isomerohydrolase, Retinol Binding Protein 4, and Transthyretin.
-
What are the mechanisms of action of the Juvenile Macular Degeneration pipeline drugs market?
Some of the mechanisms of action of the Juvenile Macular Degeneration pipeline drugs market are Retinal Specific ATP Binding Cassette Transporter Activator, Acetylcholinesterase Inhibitor, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Complement C5 Inhibitor, Complement Factor D Inhibitor, Peroxisome Proliferator Activated Receptor Alpha Agonist, Peroxisome Proliferator Activated Receptor Delta Agonist, Peroxisome Proliferator Activated Receptor Gamma Agonist, Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/KInhibitor, Retinoid Isomerohydrolase Inhibitor, Retinol Binding Protein 4 Inhibitor, and Transthyretin Inhibitor.
-
What are the routes of administration in the Juvenile Macular Degeneration pipeline drugs market?
The routes of administration in the Juvenile Macular Degeneration pipeline drugs market are oral, intravitreal, intraocular, ophthalmic, and subcutaneous.
-
What are the molecule types in the Juvenile Macular Degeneration pipeline drugs market?
The molecule types in the Juvenile Macular Degeneration pipeline drugs market are gene therapy, small molecule, cell therapy, aptamer, antisense oligonucleotide, antisense RNAi oligonucleotide, and recombinant enzyme.
-
Which are the key companies in the Juvenile Macular Degeneration pipeline drugs market?
Some of the key companies in the Juvenile Macular Degeneration pipeline drugs market are Astellas Pharma Inc, IVERIC bio Inc, 4P-Pharma SAS, Alkeus Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Alpine Biotherapeutics Corp, Applied Genetic Technologies Corp, Beam Therapeutics Inc, Belite Bio Inc, and Biophytis SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Ophthalmology reports